/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Rimini Street Announces Fiscal First Quarter 2019 Financial Results
![](https://i2.wp.com/picante.today/wp-content/uploads/2019/05/PR_Q1.jpg?fit=150%2C150&ssl=1)
Quarterly revenue of $66.3 million, up 11% year over year
Quarterly gross margin of 64%, up from 61% year over year
1,852 active clients at March 31, 2019, up 17% year over year
LAS VEGAS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/RMNI?src=hash” target=”_blank”gt;#RMNIlt;/agt;–Rimini
Street, Inc. (Nasdaq: RMNI), a global provider of enterprise
software products and services, the leading third-party support provider
for Oracle and SAP software products and a Salesforce partner, today
announced results for the first quarter ended March 31, 2019.
“During the first quarter, we made meaningful progress expanding sales
capacity, improving our global service delivery model and launching and
selling Salesforce.com and other new support services that increase our
total addressable market,” stated Seth
A. Ravin, Rimini Street co-founder, CEO and Chairman of the Board.
“Additionally, in March we prevailed against Oracle in the U.S. Supreme
Court with a unanimous decision. Oracle was ordered to return
approximately $12.8 million plus interest and other costs to Rimini
Street, which Oracle paid in April.”
“Revenue in the first quarter exceeded the high end of our guidance
range and we achieved a better than expected gross margin of 64%,”
stated Tom
Sabol, Rimini Street CFO. “We managed sales and marketing and
general and administrative spend within our guidance range, completed an
additional Series A Preferred financing round to fund new product and
service launches and further strengthen our balance sheet. We remain
committed to the long-term goals of improving free cash flow and
achieving GAAP profitability.”
First Quarter 2019 Financial Highlights
-
Revenue was $66.3 million for the 2019 first quarter, an increase of
11% compared to $59.8 million for the same period last year. -
Annualized Subscription Revenue was approximately $265 million for the
2019 first quarter, an increase of 11% compared to $239 million for
the same period last year. -
Active Clients as of March 31, 2019 were 1,852, an increase of 17%
compared to 1,581 Active Clients as of March 31, 2018. -
Revenue Retention Rate was 92.0% for the trailing 12 months ended
March 31, 2019 compared to 93.0% for the comparable period ended March
31, 2018. -
Gross margin was 64.0% for the 2019 first quarter compared to 60.6%
for the same period last year. -
Operating income was $12.7 million for the 2019 first quarter compared
to $25.2 million for the same period last year. -
Non-GAAP Operating Income was $7.8 million for the 2019 first quarter
compared to $6.1 million for the same period last year. -
Net income was $11.8 million for the 2019 first quarter compared to a
net income of $3.5 million for the same period last year. -
Non-GAAP Net Income was $6.7 million for the 2019 first quarter
compared to Non-GAAP Net Loss of $16.3 million for the same period
last year. -
Adjusted EBITDA for the 2019 first quarter was $8.1 million compared
to $6.7 million for the same period last year. -
Basic earnings per share attributable to common stockholders was $0.07
per share for the 2019 first quarter compared to $0.06 per share for
the same period last year. Diluted earnings per share attributable to
common stockholders was $0.07 per share for the 2019 first quarter
compared to $0.05 per share for the same period last year.
Reconciliations of the non-GAAP financial measures provided in this
press release to their most directly comparable GAAP financial measures
are provided in the financial tables included at the end of this press
release. An explanation of these measures and how they are calculated is
also included under the heading “About Non-GAAP Financial Measures and
Certain Key Metrics.”
First Quarter 2019 Company Highlights
-
Announced that EBSCO Industries chose Rimini
Street Application Management Services for Salesforce to maximize
the value and ROI of their Salesforce investment. -
Announced the Supreme
Court ruled unanimously in the Company’s favor, ordering Oracle to
return approximately $12.8 million in non-taxable expenses plus
interest and other costs to Rimini Street. Oracle paid the amounts in
April. -
Announced strong government
client momentum in the ANZ region, with more than 10 Australian
government agencies switching to Rimini Street support. -
Won nine Company awards, including a Gold Stevie award for Innovation
in Customer Service, and a Gold One Planet award for Customer Service
Team of the Year. -
Closed a record number of support cases, nearly 8,000, and scored a
4.8 in client satisfaction (where 5.0 is excellent). -
Delivered more than 20,000 tax, legal and regulatory updates to
clients globally for Peoplesoft, JD Edwards, SAP and Oracle E-Business
Suite products. -
Presented at 12 CIO and IT procurement leader events including
Government ICT in London, England, NRF in New York, and Gartner’s EAA
Summit in Tokyo, Japan.
2019 Revenue Guidance
The Company is currently providing second quarter 2019 revenue guidance
to be in the range of approximately $66.5 million to $67.5 million and
reiterating full year 2019 revenue guidance to be in the range of
approximately $265 million to $280 million.
Webcast and Conference Call Information
Rimini Street will host a conference call and webcast to discuss the
first quarter 2019 results at 5:00 p.m. Eastern / 2:00 p.m. Pacific time
on May 9, 2019. A live webcast of the event will be available on Rimini
Street’s Investor Relations site at https://investors.riministreet.com/events-and-presentations/upcoming-and-past-events.
Dial in participants can access the conference call by dialing (855)
213-3942 in the U.S. and Canada and enter the code 1939675. A
replay of the webcast will be available for at least 90 days following
the event.
Company’s Use of Non-GAAP Financial Measures
This press release contains certain “non-GAAP financial measures.”
Non-GAAP financial measures are not based on a comprehensive set of
accounting rules or principles. This non-GAAP information supplements,
and is not intended to represent a measure of performance in accordance
with disclosures required by U.S. generally accepted accounting
principles, or GAAP. Non-GAAP financial measures should be considered in
addition to, not as a substitute for or superior to, financial measures
determined in accordance with GAAP. A reconciliation of GAAP to non-GAAP
results is included in the financial tables included in this press
release. Presented under the heading “About Non-GAAP Financial Measures
and Certain Key Metrics” is a description and explanation of our
non-GAAP financial measures.
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise
software products and services, the leading third-party support provider
for Oracle and SAP software products and a Salesforce partner. The
Company has redefined enterprise software support services since 2005
with an innovative, award-winning program that enables licensees of IBM,
Microsoft, Oracle, Salesforce, SAP and other enterprise software vendors
to save up to 90 percent on total maintenance costs. Clients can remain
on their current software release without any required upgrades for a
minimum of 15 years. Over 1,850 global Fortune 500, midmarket, public
sector and other organizations from a broad range of industries
currently rely on Rimini Street as their trusted, third-party support
provider. To learn more, please visit http://www.riministreet.com/,
follow @riministreet on
Twitter and find Rimini Street on Facebook
and LinkedIn.
(IR-RMNI)
Forward-Looking Statements
Certain statements included in this communication are not historical
facts but are forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally are accompanied by words such as
“may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,”
“estimate,” “predict,” “potential,” “seem,” “seek,” “continue,”
“future,” “will,” “expect,” “outlook” or other similar words, phrases or
expressions. These forward-looking statements include, but are not
limited to, statements regarding our expectations of future events,
future opportunities, global expansion and other growth initiatives and
our investments in such initiatives. These statements are based on
various assumptions and on the current expectations of management and
are not predictions of actual performance, nor are these statements of
historical facts. These statements are subject to a number of risks and
uncertainties regarding Rimini Street’s business, and actual results may
differ materially. These risks and uncertainties include, but are not
limited to, changes in the business environment in which Rimini Street
operates, including inflation and interest rates, and general financial,
economic, regulatory and political conditions affecting the industry in
which Rimini Street operates; adverse developments in pending litigation
or in the government inquiry or any new litigation; the final amount and
timing of any refunds from Oracle related to our litigation; our need
and ability to raise additional equity or debt financing on favorable
terms and our ability to generate cash flows from operations to help
fund increased investment in our growth initiatives; the sufficiency of
our cash and cash equivalents to meet our liquidity requirements; the
terms and impact of our outstanding 13.00% Series A Preferred Stock;
changes in taxes, laws and regulations; competitive product and pricing
activity; difficulties of managing growth profitably; the success of our
recently introduced products and services, including Rimini Street
Mobility, Rimini Street Analytics, Rimini Street Advanced Database
Security, and services for Salesforce Sales Cloud and Service Cloud
products, in addition to products and services we expect to introduce in
the near future; the loss of one or more members of Rimini Street’s
management team; uncertainty as to the long-term value of Rimini
Street’s equity securities; and those discussed under the heading “Risk
Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on May
9, 2019, and as updated from time to time by Rimini Street’s future
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K, and other filings by Rimini Street with the
Securities and Exchange Commission. In addition, forward-looking
statements provide Rimini Street’s expectations, plans or forecasts of
future events and views as of the date of this communication. Rimini
Street anticipates that subsequent events and developments will cause
Rimini Street’s assessments to change. However, while Rimini Street may
elect to update these forward-looking statements at some point in the
future, Rimini Street specifically disclaims any obligation to do so,
except as required by law. These forward-looking statements should not
be relied upon as representing Rimini Street’s assessments as of any
date subsequent to the date of this communication.
© 2019 Rimini Street, Inc. All rights reserved. “Rimini Street” is a
registered trademark of Rimini Street, Inc. in the United States and
other countries, and Rimini Street, the Rimini Street logo, and
combinations thereof, and other marks marked by TM are trademarks of
Rimini Street, Inc. All other trademarks remain the property of their
respective owners, and unless otherwise specified, Rimini Street claims
no affiliation, endorsement, or association with any such trademark
holder or other companies referenced herein.
RIMINI STREET, INC. |
||||||||
Unaudited Condensed Consolidated Balance Sheets |
||||||||
(In thousands, except per share amounts) |
||||||||
ASSETS |
March 31, 2019 |
December 31, 2018 |
||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 32,264 | $ | 24,771 | ||||
Restricted cash | 435 | 435 | ||||||
Accounts receivable, net of allowance of $296 and $489, respectively | 63,642 | 80,599 | ||||||
Other receivable | 12,987 | — | ||||||
Prepaid expenses and other | 8,842 | 7,099 | ||||||
Total current assets | 118,170 | 112,904 | ||||||
Long-term assets: | ||||||||
Property and equipment, net of accumulated depreciation and amortization of $9,037 and $8,543, respectively |
3,673 | 3,634 | ||||||
Deposits and other | 1,406 | 1,438 | ||||||
Deferred income taxes, net | 934 | 909 | ||||||
Total assets | $ | 124,183 | $ | 118,885 | ||||
LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | ||||||||
Current liabilities: | ||||||||
Current maturities of long-term debt | $ | 1,222 | $ | 2,372 | ||||
Accounts payable | 2,921 | 12,851 | ||||||
Accrued compensation, benefits and commissions | 18,922 | 22,503 | ||||||
Other accrued liabilities | 25,094 | 20,424 | ||||||
Deferred revenue | 180,580 | 180,358 | ||||||
Total current liabilities | 228,739 | 238,508 | ||||||
Long-term liabilities: | ||||||||
Deferred revenue | 28,148 | 28,898 | ||||||
Accrued PIK dividends payable | 1,059 | 1,056 | ||||||
Other long-term liabilities | 2,038 | 2,011 | ||||||
Total liabilities | 259,984 | 270,473 | ||||||
Redeemable Series A Preferred Stock: | ||||||||
Authorized 180 shares; issued and outstanding 148 shares and 141 as of March 31, 2019 and December 31, 2018, respectively. Liquidation preference of $148,408, net of discount for $27,557 and $140,846, net of discount for $26,848, as of March 31, 2019 and December 31, 2018, respectively |
120,851 | 113,998 | ||||||
Stockholders’ deficit: | ||||||||
Preferred Stock, $0.0001 par value per share. Authorized 99,820 shares (exclusive of
180 shares of Series A Preferred Stock); no other series has been |
— | — | ||||||
Common Stock, $0.0001 par value. Authorized 1,000,000 shares; issued and outstanding 65,242 and 64,193 shares as of March 31, 2019 and December 31, 2018, respectively |
7 | 6 | ||||||
Additional paid-in capital | 105,455 | 108,347 | ||||||
Accumulated other comprehensive loss | (1,566 | ) | (1,567 | ) | ||||
Accumulated deficit | (360,548 | ) | (372,372 | ) | ||||
Total stockholders’ deficit | (256,652 | ) | (265,586 | ) | ||||
Total liabilities, redeemable preferred stock and stockholders’ deficit |
$ | 124,183 | $ | 118,885 | ||||
RIMINI STREET, INC. |
||||||||
Unaudited Condensed Consolidated Statements of Operations |
||||||||
(In thousands, except per share amounts) |
||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2019 | 2018 | |||||||
Revenue | $ | 66,260 | $ | 59,805 | ||||
Cost of revenue | 23,837 | 23,541 | ||||||
Gross profit | 42,423 | 36,264 | ||||||
Operating expenses: | ||||||||
Sales and marketing | 23,376 | 20,207 | ||||||
General and administrative | 12,424 | 10,805 | ||||||
Litigation costs and related recoveries: | ||||||||
Professional fees and other defense costs of litigation | 2,041 | 8,899 | ||||||
Litigation appeal refunds | (12,775 | ) | (21,285 | ) | ||||
Insurance costs and recoveries, net | 4,639 | (7,583 | ) | |||||
Litigation costs and related recoveries, net | (6,095 | ) | (19,969 | ) | ||||
Total operating expenses | 29,705 | 11,043 | ||||||
Operating income | 12,718 | 25,221 | ||||||
Non-operating expenses: | ||||||||
Interest expense | (232 | ) | (13,409 | ) | ||||
Other debt financing expenses | — | (8,617 | ) | |||||
Gain from change in fair value of embedded derivatives | — | 500 | ||||||
Other income, net | 43 | 328 | ||||||
Income before income taxes | 12,529 | 4,023 | ||||||
Income tax expense | (705 | ) | (516 | ) | ||||
Net income | $ | 11,824 | $ | 3,507 | ||||
Net income attributable to common stockholders | $ | 4,740 | $ | 3,507 | ||||
Net earnings per share attributable to common stockholders: | ||||||||
Basic | $ | 0.07 | $ | 0.06 | ||||
Diluted | $ | 0.07 | $ | 0.05 | ||||
Weighted average number of shares of Common Stock outstanding: | ||||||||
Basic | 64,622 | 59,393 | ||||||
Diluted | 69,101 | 68,154 | ||||||
RIMINI STREET, INC. |
||||||||
GAAP to Non-GAAP Reconciliations |
||||||||
(In thousands) |
||||||||
Three Months Ended | ||||||||
March 31, | ||||||||
2019 | 2018 | |||||||
Non-GAAP operating income reconciliation: | ||||||||
Operating income | $ | 12,718 | $ | 25,221 | ||||
Non-GAAP adjustments: | ||||||||
Litigation costs and recoveries, net | (6,095 | ) | (19,969 | ) | ||||
Stock-based compensation expense | 1,155 | 867 | ||||||
Non-GAAP operating income | $ | 7,778 | $ | 6,119 | ||||
Non-GAAP net income (loss) reconciliation: | ||||||||
Net income | $ | 11,824 | $ | 3,507 | ||||
Non-GAAP adjustments: | ||||||||
Litigation costs and recoveries, net | (6,095 | ) | (19,969 | ) | ||||
Post-judgment interest in litigation awards | (212 | ) | (199 | ) | ||||
Stock-based compensation expense | 1,155 | 867 | ||||||
Gain from change in fair value of embedded derivatives | — | (500 | ) | |||||
Non-GAAP net income (loss) | $ | 6,672 | $ | (16,294 | ) | |||
Non-GAAP Adjusted EBITDA reconciliation: | ||||||||
Net income | $ | 11,824 | $ | 3,507 | ||||
Non-GAAP adjustments: | ||||||||
Interest expense | 232 | 13,409 | ||||||
Income tax expense | 705 | 516 | ||||||
Depreciation and amortization expense | 494 | 484 | ||||||
EBITDA | 13,255 | 17,916 | ||||||
Non-GAAP adjustments: | ||||||||
Litigation costs and recoveries, net | (6,095 | ) | (19,969 | ) | ||||
Post-judgment interest in litigation awards | (212 | ) | (199 | ) | ||||
Stock-based compensation expense | 1,155 | 867 | ||||||
Gain from change in fair value of embedded derivatives | — | (500 | ) | |||||
Other debt financing expenses | — | 8,617 | ||||||
Adjusted EBITDA | $ | 8,103 | $ | 6,732 | ||||
About Non-GAAP Financial Measures and Certain Key Metrics
To provide investors and others with additional information regarding
Rimini Street’s results, we have disclosed the following non-GAAP
financial measures and certain key metrics. We have described below
Active Clients, Annualized Subscription Revenue and Revenue Retention
Rate, each of which is a key operational metric for our business. In
addition, we have disclosed the following non-GAAP financial measures:
non-GAAP operating income, non-GAAP net income (loss), EBITDA, and
adjusted EBITDA. Rimini Street has provided in the tables above a
reconciliation of each non-GAAP financial measure used in this earnings
release to the most directly comparable GAAP financial measure. Due to a
valuation allowance for our deferred tax assets, there were no tax
effects associated with any of our non-GAAP adjustments. These non-GAAP
financial measures are also described below.
The primary purpose of using non-GAAP measures is to provide
supplemental information that management believes may prove useful to
investors and to enable investors to evaluate our results in the same
way management does. We also present the non-GAAP financial measures
because we believe they assist investors in comparing our performance
across reporting periods on a consistent basis, as well as comparing our
results against the results of other companies, by excluding items that
we do not believe are indicative of our core operating performance.
Specifically, management uses these non-GAAP measures as measures of
operating performance; to prepare our annual operating budget; to
allocate resources to enhance the financial performance of our business;
to evaluate the effectiveness of our business strategies; to provide
consistency and comparability with past financial performance; to
facilitate a comparison of our results with those of other companies,
many of which use similar non-GAAP financial measures to supplement
their GAAP results; and in communications with our board of directors
concerning our financial performance. Investors should be aware however,
that not all companies define these non-GAAP measures consistently.
Active Client is a distinct entity that purchases our services to
support a specific product, including a company, an educational or
government institution, or a business unit of a company. For example, we
count as two separate active clients when support for two different
products is being provided to the same entity. We believe that our
ability to expand our active clients is an indicator of the growth of
our business, the success of our sales and marketing activities, and the
value that our services bring to our clients.
Annualized Subscription Revenue is the amount of subscription
revenue recognized during a fiscal quarter and multiplied by four. This
gives us an indication of the revenue that can be earned in the
following 12-month period from our existing client base assuming no
cancellations or price changes occur during that period. Subscription
revenue excludes any non-recurring revenue, which has been insignificant
to date.
Revenue Retention Rate is the actual subscription revenue
(dollar-based) recognized over a 12-month period from customers that
were clients on the day prior to the start of such 12-month period,
divided by our Annualized Subscription Revenue as of the day prior to
the start of the 12-month period.
Non-GAAP Operating Income is operating income adjusted to
exclude: litigation costs and recoveries, net, and stock-based
compensation expense. The exclusions are discussed in further detail
below.
Non-GAAP Net Income (Loss) is net income adjusted to
exclude: litigation costs and recoveries, net, post-judgment interest on
litigation appeal awards, stock-based compensation expense, gain from
change in fair value of embedded derivatives. These exclusions are
discussed in further detail below.
Specifically, management is excluding the following items from its
non-GAAP financial measures, as applicable, for the periods presented:
Litigation Costs and Recoveries, Net: Litigation costs and the
associated insurance and appeal recoveries relate to outside costs of
litigation activities. These costs and recoveries reflect the ongoing
litigation we are involved with, and do not relate to the day-to-day
operations or our core business of serving our clients.
Stock-Based Compensation Expense: Our compensation strategy
includes the use of stock-based compensation to attract and retain
employees. This strategy is principally aimed at aligning the employee
interests with those of our stockholders and to achieve long-term
employee retention, rather than to motivate or reward operational
performance for any particular period. As a result, stock-based
compensation expense varies for reasons that are generally unrelated to
operational decisions and performance in any particular period.
Post-judgment Interest on Litigation Appeal Award: Post-judgment
interest resulted from our appeals of ongoing litigation and does not
relate to the day-to-day operations or our core business of serving our
clients.
Gain from Change in Fair Value of Embedded Derivatives: Our
former credit facility included features that were determined to be
embedded derivatives requiring bifurcation and accounting as separate
financial instruments. We have determined to exclude the gains and
losses on embedded derivatives related to the change in fair value of
these instruments given the financial nature of this fair value
requirement. We were not able to manage these amounts as part of our
business operations, nor were the costs core to servicing our clients,
so we have excluded them.
Other Debt Financing Expenses: Other debt financing expenses
included non-cash write-offs (including write-offs due to payoff),
accretion, amortization of debt discounts and issuance costs, and
collateral monitoring and other fees payable in cash related to our
former credit facility. Since these amounts related to our debt
financing structure, we have excluded them since they do not relate to
the day-to-day operations or our core business of serving our clients.
EBITDA is net income adjusted to exclude: interest expense,
income tax expense, and depreciation and amortization expense.
Adjusted EBITDA is EBITDA adjusted to exclude: litigation costs
and recoveries, net, post-judgment interest on litigation appeal award,
stock-based compensation expense, gain from change in fair value of
embedded derivatives, and other debt financing expenses, as discussed
above.
Contacts
Investor Relations Contact
Dean
Pohl
Rimini Street, Inc.
+1 203 347-4446
dpohl@riministreet.com
Media Relations Contact
Michelle
McGlocklin
Rimini Street, Inc.
+1 925 523-8414
mmcglocklin@riministreet.com
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Innocan
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
![innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center](https://grassnews.net/wp-content/uploads/2024/07/61449-innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center.jpg)
HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.
The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.
Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.
“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”
Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html
Cannabis
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location
![](https://grassnews.net/wp-content/uploads/2024/07/verano-announces-the-opening-of-zen-leaf-fairless-hills-the-companys-newest-affiliated-dispensary-in-pennsylvania-in-prime-new-location.gif)
- Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
- As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
- Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.
The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.
“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”
Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.
About Verano
Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf™ and MÜV™ dispensary banners, including Cabbage Club™, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano™, (the) Essence™, MÜV™, Savvy™, BITS™, Encore™, and Avexia™. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.
Contacts:
Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.
###
1 Pennsylvania Department of Transportation
2 United States Census Bureau
Cannabis
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
![](https://grassnews.net/wp-content/uploads/2024/07/unlocking-new-horizons-in-health-tnr-the-niche-research-reveals-the-transformative-power-of-minor-cannabinoids.gif)
Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.
Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.
Global Minor Cannabinoids Market: Key Datapoints
Market Value in 2023 |
US$ 17.8 Bn |
Market Value Forecast by 2034 |
US$ 42.3 Bn |
Growth Rate
|
8.2% |
Historical Data
|
2016 – 2022 |
Base Year
|
2023 |
Forecast Data
|
2024 – 2034 |
Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.
The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.
The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.
The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.
Global Minor Cannabinoids Market: Key Takeaways of the Report
- Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
- Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
- In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.
Key Development:
- In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
- In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.
Browse Related Category Reports
Global Minor Cannabinoids Market:
- Aurora Europe GmbH
- BulKanna
- CBD. INC.
- Fresh Bros Hemp Company
- GCM Holdings, LLC (Global Cannabinoids)
- GenCanna.
- High Purity Natural Products.
- Laurelcrest
- Mile High Labs
- PBG Global
- Rhizo Sciences
- ZERO POINT EXTRACTION, LLC
- Other Industry Participants
Global Minor Cannabinoids Market
By Product Type
- Cannabigerol (CBG)
- Cannabichromene (CBC)
- Cannabinol (CBN)
- Cannabidivarin (CBDV)
- Tetrahydrocannabutol (THCB)
- Tetrahydrocannabivarin (THCV)
- Tetrahydrocannabiphorol (THCP)
- Others
By Application
- Pharmaceutical
- Pain Management
- Mental Health
- Sleep Disorders
- Anti-inflammatory
- Others
- Nutraceuticals
- Cosmetics and Personal Care
- Food and Beverages
- Others
By Region
- North America (U.S., Canada, Mexico, Rest of North America)
- Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
- Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
- Latin America (Brazil, Argentina, Rest of Latin America)
Consult with Our Expert:
Jay Reynolds
The Niche Research
Japan (Toll-Free): +81 663-386-8111
South Korea (Toll-Free): +82-808- 703-126
Saudi Arabia (Toll-Free): +966 800-850-1643
United Kingdom: +44 753-710-5080
United States: +1 302-232-5106
Email: askanexpert@thenicheresearch.com
Website: www.thenicheresearch.com
-
Cannabis2 weeks ago
IM Cannabis Shares Commence Trading on 6:1 Consolidated Basis
-
Cannabis2 weeks ago
Fractional Flow Reserve Market growing at a CAGR of 15.56% during the forecast period [2024-2030] – Exactitude Consultancy
-
Cannabis1 week ago
Blank Rome Bolsters Energy Industry Team in Houston and Pittsburgh with Leading Transactional Group
-
Cannabis1 week ago
Manitoba Harvest Hemp Foods and Brightseed® Introduce New Coffee and Chocolate Flavors in Organic Bioactive Fiber Supplement for Gut Health
-
Cannabis4 days ago
Europe Medical Cannabis Oil Market Set to Reach Valuation of USD 2,395.83 Million by 2032 | Astute Analytica
-
Cannabis4 days ago
Global Agricultural Textiles Market Size To Worth USD 25.02 Billion By 2033 | CAGR of 4.70%
-
Cannabis1 day ago
Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids
-
Cannabis15 hours ago
Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location